Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

775
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
775
Teratogenicity01:07

Teratogenicity

4.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

101
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
101
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Oogenesis02:07

Oogenesis

71.0K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
71.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

520
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
520

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Australian MotherSafe enhanced service for nausea and vomiting in pregnancy and hyperemesis gravidarum: a mixed methods study.

BMC pregnancy and childbirth·2026
Same author

Paracetamol in Pregnancy: Uncertain Evidence, Certain Consequences.

The Medical journal of Australia·2026
Same author

Letter in response to article "Fertility after cancer" by J Malhotra et al Int J Obstet Gynecol 2025;169:883-890)".

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same author

Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies.

Drugs·2026
Same author

Beating the Odds: A Successful Pregnancy in a Patient With ALK-Rearranged Lung Cancer on Alectinib.

Case reports in medicine·2025
Same author

In Reply.

Obstetrics and gynecology·2025

Related Experiment Video

Updated: Mar 16, 2026

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

17.4K

Ondansetron and pregnancy: Understanding the data.

Debra Kennedy1

  • 1Royal Hospital for Women, Randwick, NSW, Australia; School of Women's and Children's Health, University of NSW, Kensington, NSW, Australia.

Obstetric Medicine
|August 12, 2016
PubMed
Summary

Nausea and vomiting of pregnancy (NVP) affects most pregnant women, often during early embryonic development. While ondansetron use for NVP has increased, its safety data remains limited, necessitating careful treatment guidelines.

Keywords:
Nausea and vomiting of pregnancybirth defectshyperemesis gravidarummedicationsondansetron

More Related Videos

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

2.4K
Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes
04:08

Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes

Published on: June 27, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 16, 2026

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

17.4K
Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

2.4K
Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes
04:08

Mouse Model of Surgical Uterine Injury and Subsequent Pregnancy Outcomes

Published on: June 27, 2025

1.3K

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Teratology

Background:

  • Nausea and vomiting of pregnancy (NVP) is highly prevalent, affecting up to 75% of pregnant individuals.
  • Symptoms typically emerge in the first trimester, peaking between weeks 7-12, and usually resolve by week 20.
  • The critical period for embryonic development, when susceptibility to teratogenic risks is highest, overlaps with the peak NVP symptom duration.

Purpose of the Study:

  • To review the challenges in interpreting safety data for medications used to treat NVP.
  • To discuss the increased off-label use of ondansetron for NVP despite limited evidence of superior efficacy and safety.
  • To emphasize the need for adherence to established treatment guidelines for NVP.

Main Methods:

  • Literature review of studies on NVP treatments, focusing on ondansetron.
  • Analysis of available human pregnancy data regarding ondansetron use.
  • Examination of the historical context and sensitivity surrounding medication use during pregnancy, referencing the thalidomide tragedy.

Main Results:

  • Ondansetron has shown no clear benefits over other NVP treatments like doxylamine in several studies.
  • Despite limited safety data, off-label ondansetron prescription for NVP has significantly increased globally.
  • Current limited human pregnancy data does not indicate a significantly increased risk of birth defects or adverse outcomes with ondansetron use.

Conclusions:

  • Interpreting the available data on NVP treatments, particularly ondansetron, presents significant challenges.
  • The increased use of ondansetron for NVP warrants careful consideration due to the paucity of comprehensive safety data.
  • Adherence to practical clinical guidelines is crucial for the safe and effective management of NVP.